Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.

Remy-Ziller C, Thioudellet C, Hortelano J, Gantzer M, Nourtier V, Claudepierre MC, Sansas B, Préville X, Bendjama K, Quemeneur E, Rittner K.

Hum Vaccin Immunother. 2018 Jan 2;14(1):140-145. doi: 10.1080/21645515.2017.1373921. Epub 2017 Oct 18.

2.

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.

Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, Limacher JM, Quemeneur E, Bendjama K, Préville X.

J Immunother Cancer. 2017 Sep 19;5(1):70. doi: 10.1186/s40425-017-0274-x.

3.

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy.

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V, Préville X, Quéméneur E, Kepp O, Adam J, Marabelle A, Pitt JM, Kroemer G, Zitvogel L.

Cancer Res. 2017 Aug 1;77(15):4146-4157. doi: 10.1158/0008-5472.CAN-16-2165. Epub 2017 May 23.

4.

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.

Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, Lusky M, Erbs P, Preville X, Moehler M.

Onco Targets Ther. 2017 May 2;10:2389-2401. doi: 10.2147/OTT.S126320. eCollection 2017.

5.

Typing of killer-cell immunoglobulin-like receptors and their cognate human leukocyte antigen class I ligands predicts survival of Chinese Han patients with metastatic non-small-cell lung cancer.

Yu H, Liu F, Sansas B, Kang B, Preville X, Wu X, Chang J, Micol R, Wang J, Meng X.

Mol Clin Oncol. 2017 Feb;6(2):279-285. doi: 10.3892/mco.2016.1106. Epub 2016 Dec 12.

6.

Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.

Schaedler E, Remy-Ziller C, Hortelano J, Kehrer N, Claudepierre MC, Gatard T, Jakobs C, Préville X, Carpentier AF, Rittner K.

Vaccine. 2017 Jan 23;35(4):577-585. doi: 10.1016/j.vaccine.2016.12.020. Epub 2016 Dec 21.

PMID:
28012777
7.

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.

Kleinpeter P, Fend L, Thioudellet C, Geist M, Sfrontato N, Koerper V, Fahrner C, Schmitt D, Gantzer M, Remy-Ziller C, Brandely R, Villeval D, Rittner K, Silvestre N, Erbs P, Zitvogel L, Quéméneur E, Préville X, Marchand JB.

Oncoimmunology. 2016 Sep 9;5(10):e1220467. eCollection 2016.

8.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

9.

Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.

Fend L, Remy-Ziller C, Foloppe J, Kempf J, Cochin S, Barraud L, Accart N, Erbs P, Fournel S, Préville X.

Oncoimmunology. 2015 Oct 6;5(2):e1080414. eCollection 2016 Feb.

10.

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand.

Préville X, Rittner K, Fend L.

Oncoimmunology. 2015 Feb 3;4(5):e1003013. eCollection 2015 May.

11.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
12.

Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist.

Fend L, Gatard-Scheikl T, Kintz J, Gantzer M, Schaedler E, Rittner K, Cochin S, Fournel S, Préville X.

Cancer Immunol Res. 2014 Dec;2(12):1163-74. doi: 10.1158/2326-6066.CIR-14-0050. Epub 2014 Aug 28.

13.

Trial Watch:: Oncolytic viruses for cancer therapy.

Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jun 1;3:e28694. eCollection 2014. Review.

14.

Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.

Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C, Thioudellet C, Ancian P, Lux A, Sehnert B, Nimmerjahn F, Voll RE, Schett G.

Arthritis Rheumatol. 2014 Nov;66(11):2989-3000. doi: 10.1002/art.38624.

15.

Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy.

Claudepierre MC, Hortelano J, Schaedler E, Kleinpeter P, Geist M, Remy-Ziller C, Brandely R, Tosch C, Laruelle L, Jawhari A, Menguy T, Marchand JB, Romby P, Schultz P, Hartmann G, Rooke R, Bonnefoy JY, Preville X, Rittner K.

J Virol. 2014 May;88(10):5242-55. doi: 10.1128/JVI.03819-13. Epub 2014 Feb 26.

16.

Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.

Remy-Ziller C, Germain C, Spindler A, Hoffmann C, Silvestre N, Rooke R, Bonnefoy JY, Préville X.

Clin Vaccine Immunol. 2014 Feb;21(2):147-55. doi: 10.1128/CVI.00678-13. Epub 2013 Dec 4.

17.

Therapeutic effects of anti-CD115 monoclonal antibody in mouse cancer models through dual inhibition of tumor-associated macrophages and osteoclasts.

Fend L, Accart N, Kintz J, Cochin S, Reymann C, Le Pogam F, Marchand JB, Menguy T, Slos P, Rooke R, Fournel S, Bonnefoy JY, Préville X, Haegel H.

PLoS One. 2013 Sep 3;8(9):e73310. doi: 10.1371/journal.pone.0073310. eCollection 2013.

18.

A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells.

Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, Marchand JB, Toh ML, Duong V, Calcei A, Settelen N, Preville X, Hennequi M, Grellier B, Ancian P, Rissanen J, Clayette P, Guillen C, Rooke R, Bonnefoy JY.

MAbs. 2013 Sep-Oct;5(5):736-47. doi: 10.4161/mabs.25743. Epub 2013 Jul 15.

19.

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.

Amiset L, Fend L, Gatard-Scheikl T, Rittner K, Duong V, Rooke R, Muller S, Bonnefoy JY, Préville X, Haegel H.

Oncoimmunology. 2012 Nov 1;1(8):1271-1280.

20.

Improving administration regimens of CyaA-based vaccines using TRAP assays to detect antigen-specific CD8(+) T cells directly ex vivo.

Daubeuf S, Préville X, Momot M, Misseri Y, Joly E, Hudrisier D.

Vaccine. 2009 Sep 18;27(41):5565-73. doi: 10.1016/j.vaccine.2009.07.035. Epub 2009 Jul 31.

PMID:
19647811
22.

Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system.

Berraondo P, Nouzé C, Préville X, Ladant D, Leclerc C.

Cancer Res. 2007 Sep 15;67(18):8847-55.

23.

A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cell reactivity by flow cytometry.

Puaux AL, Campanaud J, Salles A, Préville X, Timmerman B, Joly E, Hudrisier D.

Eur J Immunol. 2006 Mar;36(3):779-88.

25.

Cathepsin-B-dependent apoptosis triggered by antithymocyte globulins: a novel mechanism of T-cell depletion.

Michallet MC, Saltel F, Preville X, Flacher M, Revillard JP, Genestier L.

Blood. 2003 Nov 15;102(10):3719-26. Epub 2003 Jul 31.

26.

Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins.

Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP.

Transplantation. 2003 Mar 15;75(5):657-62.

PMID:
12640305
27.

Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model.

Préville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, Revillard JP.

Transplantation. 2001 Feb 15;71(3):460-8.

PMID:
11233911
28.

First human hand transplantation. Case report.

Dubernard JM, Owen E, Lefrançois N, Petruzzo P, Martin X, Dawahra M, Jullien D, Kanitakis J, Frances C, Preville X, Gebuhrer L, Hakim N, Lanzettà M, Kapila H, Herzberg G, Revillard JP.

Transpl Int. 2000;13 Suppl 1:S521-4. No abstract available.

PMID:
11112064
29.

A quantitative flow cytometry assay for the preclinical testing and pharmacological monitoring of rabbit antilymphocyte globulins (rATG).

Préville X, Nicolas L, Flacher M, Revillard J.

J Immunol Methods. 2000 Nov 1;245(1-2):45-54.

PMID:
11042282
30.

Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation.

Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP, Buchner J, Gaestel M.

J Biol Chem. 1999 Jul 2;274(27):18947-56.

31.

TNF alpha and CD95-L contribute to apoptosis of activated lymphocytes triggered by ATGs.

Bonnefoy-Berard N, Genestier L, Preville X, Revillard JP.

Transplant Proc. 1999 Feb-Mar;31(1-2):775-7. No abstract available.

PMID:
10083328
32.

Supplemental Content

Loading ...
Support Center